Previous 10 | Next 10 |
NEW HAVEN, Conn., Jan. 04, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, P...
Two Phase 3 studies to enroll a total of 300 patients in assisted living or residential facilities and nursing homes to evaluate the safety and efficacy of BXCL501 Studies designed to maximize BXCL501 opportunity to treat full spectrum of agitation, with an estimated 100 million...
The FDA extended BTAI's PDUFA by three months, tanking the stock. From every angle, the delay seems benign, and approval seems certain. That makes the slump a buying opportunity. For further details see: BioXcel: Slump After PDUFA Extension Presents Buying Opportunity
Shares of BioXcel Therapeutics (NASDAQ: BTAI) were down by 11.6% as of 3:08 p.m. ET Wednesday. The biotech's shares are retreating today in response to the Food and Drug Administration's decision to extend the review date under the Prescription Drug User Fee Act (PDUFA) for the ...
BioXcel Therapeutics (NASDAQ:BTAI) drops 22.8% premarket in reaction to the announcement that the FDA has extended the PDUFA date for its review of the New Drug Application (NDA) of BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar diso...
PDUFA date extended by three months to April 5, 2022 No Additional Data Requested Following Meeting with FDA NEW HAVEN, Conn., Dec. 01, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intel...
Shares of BioXcel (NASDAQ: BTAI) , a pre-commercial stage biopharmaceutical company, are under pressure this week. A double downgrade from Goldman Sachs analyst Corinne Jenkins from buy to sell has investors thinking twice about a potential new drug launch that could begin in ea...
Shares of BioXcel Therapeutics (NASDAQ: BTAI) had crashed 22.5% as of 11:56 a.m. EST on Monday. The steep decline came after Goldman Sachs (NYSE: GS) analyst Corinne Jenkins downgraded BioXcel from neutral to sell. Jenkins also cut the price target for the biotech stoc...
Gainers: Creative Realities (NASDAQ:CREX) +128%. Casper Sleep (NYSE:CSPR) +86%. Siyata Mobile (NASDAQ:SYTA) +33%. Patriot National Bancorp (NASDAQ:PNBK) +35%. SilverSun Technologies (NASDAQ:SSNT) +26%. The Vita CoCo (NASDAQ:COCO) +24%. Trio-Tech (NYSE:TRT) +24%. Gores Guggenheim (NASDAQ:GGPI)...
Shares of BioXcel Therapeutics (BTAI -21.5%) are down significantly today after Goldman Sachs downgraded the stock to sell from buy. Analyst Corinne Jenkins lowered her price target to $24 from $55 (~30% downside). She notes that the company's consensus estimates don't take into account ...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...